Cargando…
Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350658/ https://www.ncbi.nlm.nih.gov/pubmed/34430554 http://dx.doi.org/10.21037/atm-21-1103 |
| _version_ | 1783735815519600640 |
|---|---|
| author | Santi, Daniel V. Cabel, Luc Bidard, François-Clément |
| author_facet | Santi, Daniel V. Cabel, Luc Bidard, François-Clément |
| author_sort | Santi, Daniel V. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8350658 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83506582021-08-23 Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? Santi, Daniel V. Cabel, Luc Bidard, François-Clément Ann Transl Med Editorial Commentary AME Publishing Company 2021-07 /pmc/articles/PMC8350658/ /pubmed/34430554 http://dx.doi.org/10.21037/atm-21-1103 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Santi, Daniel V. Cabel, Luc Bidard, François-Clément Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? |
| title | Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? |
| title_full | Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? |
| title_fullStr | Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? |
| title_full_unstemmed | Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? |
| title_short | Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both? |
| title_sort | does sacituzumab-govitecan act as a conventional antibody drug conjugate (adc), a prodrug of sn-38 or both? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350658/ https://www.ncbi.nlm.nih.gov/pubmed/34430554 http://dx.doi.org/10.21037/atm-21-1103 |
| work_keys_str_mv | AT santidanielv doessacituzumabgovitecanactasaconventionalantibodydrugconjugateadcaprodrugofsn38orboth AT cabelluc doessacituzumabgovitecanactasaconventionalantibodydrugconjugateadcaprodrugofsn38orboth AT bidardfrancoisclement doessacituzumabgovitecanactasaconventionalantibodydrugconjugateadcaprodrugofsn38orboth |